BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024
Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024
Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25
Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline
Article content
SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025.
Article content
'Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven ability to deliver sustainable, long-term growth,' said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. 'We are executing with purpose and advancing our mission to deliver transformative medicines to more patients worldwide. BRUKINSA, the backbone of our hematology franchise, continues to set the standard as the best-in-class BTK inhibitor with the most approved indications and market leader in the US, a position earned from superior efficacy, favorable safety, and positive patient outcomes across its five indications. Building on this momentum, our two additional Phase 3 hematology assets, BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673, have the potential to further expand our franchise leadership with pivotal data readouts and new trial initiations anticipated in the near-term. At our recent Investor R&D Day, we outlined a bold path forward with more than 20 expected R&D milestones in the next 18 months. This includes potentially promising advances across our expansive solid tumor pipeline, where we are building future global franchises targeting a range of highly prevalent cancers.'
Article content
Second Quarter 2025 Financial Results
Article content
Revenue
Article content
for the second quarter of 2025 was $1.3 billion, compared to $929 million in the prior-year period driven primarily by growth in BRUKINSA (zanubrutinib) product sales in the U.S. and Europe.
Article content
Product Revenue
Article content
totaled $1.3 billion for the second quarter of 2025 compared to $921 million in the prior-year period. The increase in product revenue was primarily attributable to increased sales of BRUKINSA. The U.S. continued to be the Company's largest market, with product revenue of $685 million compared to $479 million in the prior-year period. In-licensed products from Amgen and TEVIMBRA (tislelizumab) also contributed to product revenue growth.
Article content
U.S. sales of BRUKINSA totaled $684 million in the second quarter of 2025, representing growth of 43% over the prior-year period driven primarily by robust demand growth across all indications and modest benefit due to net pricing. BRUKINSA continues to maintain its leading new patient share across the BTKi class due to its differentiated, best-in-class clinical profile. BRUKINSA sales in Europe totaled $150 million in the second quarter of 2025, representing growth of 85% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK.
Sales of TEVIMBRA totaled $194 million in the second quarter of 2025, representing growth of 22% compared to the prior-year period.
Article content
Gross Margin
Article content
as a percentage of global product sales for the second quarter of 2025 was 87.4% compared to 85.0% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from cost of sales productivity improvements for both BRUKINSA and TEVIMBRA. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of product sales increased to 88.1% for the second quarter of 2025, compared to 85.4% in the prior-year period.
Article content
The following table summarizes operating expenses for the first half of 2025:
Article content
increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage, and offset by lower development upfront and milestone fees. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled $0.5 million and $12 million in the second quarter of 2025 and 2024, respectively.
Article content
Selling, General and Administrative (SG&A) Expenses
Article content
increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment in global commercial expansion, primarily in the U.S. and Europe. SG&A expenses as a percentage of product sales were 41% for the second quarter of 2025, compared to 48% in the prior-year period.
Article content
Net Income/(Loss) and GAAP/Non-GAAP Earnings Per Share
Article content
GAAP net income for the second quarter of 2025 was $94 million, an increase of $215 million over the prior-year period loss, primarily attributable to revenue growth and improved operating leverage.
Article content
For the second quarter of 2025, basic and diluted earnings per share was $0.07 and $0.06 per share and $0.87 and $0.84 per American Depositary Share (ADS), respectively, compared to basic loss of $0.09 per share and $1.15 per ADS in the prior-year period.
Article content
Free Cash Flow
Article content
for the second quarter of 2025 was $220 million, an increase of $425 million over the prior-year period.
Article content
For further details on BeOne's Second Quarter 2025 Financial Statements, please see BeOne's Quarterly Report on Form 10-Q for the second quarter of 2025 filed with the U.S. Securities and Exchange Commission.
Article content
BeOne has updated its full year 2025 revenue guidance and maintained its expense guidance. Guidance is summarized below:
Article content
BeOne's total revenue guidance for full year 2025 of $5.0 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid- to high-80% range due to mix and production efficiencies as compared to 2024. BeOne's guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage. Non-GAAP operating expenses, which exclude costs related to share-based compensation, depreciation and amortization expense, are expected to track with GAAP operating expenses, with reconciling items unchanged from existing practice. Operating expense guidance does not assume any potential new, material business development activity or unusual/non-recurring items.
Article content
BRUKINSA
Article content
(zanubrutinib)
Article content
BRUKINSA is now approved in 75 markets globally with five new or expanded reimbursements in the quarter.
Received U.S. Food and Drug Administration (FDA) approval and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of a new film-coated tablet formulation for all approved indications.
Article content
TEVIMBRA
Article content
(tislelizumab)
Article content
TEVIMBRA is now approved in 47 markets globally with 20 new reimbursements in the quarter, including in Japan, Europe and Australia.
Received European Commission (EC) approval in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma.
Received EC approval for the treatment of first-line extensive-stage small cell lung cancer.
Received a positive CHMP opinion recommending approval of TEVIMBRA in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence.
Received FDA approval of alternative dosing regimens of 150 Q2W and 300 Q4W for the treatment of first-line gastric cancer and second-line esophageal squamous cell carcinoma.
Article content
Select Clinical-Stage Programs
Article content
Hematology
Article content
Sonrotoclax (BCL2 inhibitor):
Article content
Achieved acceptance of submissions in China with priority reviews for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and R/R mantle cell lymphoma (MCL).
Achieved first subject enrolled in global Phase 3 trial in combination with CD20 antibody for the treatment of R/R CLL.
Article content
BGB-16673 (BTK CDAC):
Article content
Received EMA PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor.
Achieved first subject enrolled for global Phase 3 BGB-16673-302 trial for the treatment of R/R CLL.
Achieved first subject enrolled for China Phase 3 BGB-16673-303 trial for the treatment of R/R/ CLL.
Initiated enrollment of potentially registration enabling Phase 2 trial for the treatment of R/R WM.
Article content
Lung Cancer
Article content
GI Cancers
Article content
Zanidatamab (HER2-targeting bispecific antibody): Received regulatory approval and achieved commercial launch in China for the treatment of second-line HER2-high-expression biliary tract cancer.
Article content
Inflammation & Immunology
Article content
BGB-45035 (IRAK4 CDAC): Achieved first subject enrolled in Phase 1b trial for the treatment of atopic dermatitis and prurigo nodularis.
BGB-16673 (BTK CDAC): Achieved first subject enrolled in Phase 1 trial for the treatment of chronic spontaneous urticaria.
Article content
Anticipated R&D Milestones
Article content
Other Highlights
Article content
Completed renaming to BeOne Medicines Ltd., and redomiciliation to Switzerland.
Article content
Conference Call and Webcast
Article content
The Company's earnings conference call for the second quarter 2025 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, and will be accessible through the Investors section of BeOne's website at www.beonemedicines.com. Supplemental information in the form of a slide presentation and a replay of the webcast will also be available.
Article content
About BeOne
Article content
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: upcoming R&D milestones to be achieved by BeOne; the timing of clinical developments and data readouts; BeOne's expectations regarding continued global expansion and investment to support growth; BeOne's ability to bring transformative medicines to more patients worldwide; BeOne's future revenue, operating income, cash flow, free cash flow, operating expenses, and gross margin percentage; and BeOne's plans, commitments, aspirations and goals under the caption 'About BeOne'. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne's financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
Article content
Note Regarding Use of Non-GAAP Financial Measures
Article content
BeOne provides certain non-GAAP financial measures, including Adjusted Operating Expenses, Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne's operating performance. Adjustments to BeOne's GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne's operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne's historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne's management uses for planning and forecasting purposes and measuring BeOne's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.
Article content
Three Months Ended
Six Months Ended
June 30,
June 30,
2025
2024
2025
2024
Reconciliation of GAAP to adjusted cost of sales – products:
GAAP cost of sales – products
$
164,606
$
138,132
$
329,608
$
263,067
Less: Depreciation
3,321
2,684
5,934
5,029
Less: Amortization of intangibles
5,749
1,177
6,922
2,360
Less: Other
893
—
893
—
Adjusted cost of sales – products
$
154,643
$
134,271
$
315,859
$
255,678
Reconciliation of GAAP to adjusted research and development:
GAAP research and development
$
524,896
$
454,466
$
1,006,783
$
915,104
Less: Share-based compensation cost
64,392
55,406
106,159
93,451
Less: Depreciation
16,447
16,551
35,372
33,704
Adjusted research and development
$
444,057
$
382,509
$
865,252
$
787,949
Reconciliation of GAAP to adjusted selling, general and administrative:
GAAP selling, general and administrative
$
537,913
$
443,729
$
997,201
$
871,156
Less: Share-based compensation cost
86,161
75,288
139,845
125,957
Less: Depreciation
10,086
4,519
20,162
9,131
Less: Amortization of intangibles
11
—
28
—
Adjusted selling, general and administrative
$
441,655
$
363,922
$
837,166
$
736,068
Reconciliation of GAAP to adjusted operating expenses
GAAP operating expenses
$
1,062,809
$
898,195
$
2,003,984
$
1,786,260
Less: Share-based compensation cost
150,553
130,694
246,004
219,408
Less: Depreciation
26,533
21,070
55,534
42,835
Less: Amortization of intangibles
11
—
28
—
Adjusted operating expenses
$
885,712
$
746,431
$
1,702,418
$
1,524,017
Reconciliation of GAAP to adjusted income (loss) from operations:
GAAP income (loss) from operations
$
87,885
$
(107,161
)
$
98,987
$
(368,509
)
Plus: Share-based compensation cost
150,553
130,694
246,004
219,408
Plus: Depreciation
29,854
23,754
61,468
47,864
Plus: Amortization of intangibles
5,760
1,177
6,950
2,360
Plus: Other
893
—
893
—
Adjusted income (loss) from operations
$
274,945
$
48,464
$
414,302
$
(98,877
)
Reconciliation of GAAP to adjusted net income (loss):
GAAP net income (loss)
$
94,320
$
(120,405
)
$
95,590
$
(371,555
)
Plus: Share-based compensation expenses
150,553
130,694
246,004
219,408
Plus: Depreciation
29,854
23,754
61,468
47,864
Plus: Amortization of intangibles
5,760
1,177
6,950
2,360
Plus: Other
893
—
893
—
Plus: Impairment of equity investments
3,118
—
15,494
—
Plus: Discrete tax items
(14,210
)
1,513
(8,737
)
2,403
Plus: Income tax effect of non-GAAP adjustments 1
(17,466
)
(13,439
)
(28,703
)
(23,082
)
Adjusted net income (loss)
$
252,822
$
23,294
$
388,959
$
(122,602
)
Reconciliation of GAAP to adjusted EPS – basic
GAAP earnings (loss) per share – basic
$
0.07
$
(0.09
)
$
0.07
$
(0.27
)
Plus: Share-based compensation expenses
0.11
0.10
0.18
0.16
Plus: Depreciation
0.02
0.02
0.04
0.04
Plus: Amortization of intangibles
0.00
0.00
0.00
0.00
Plus: Other
0.00
0.00
0.00
0.00
Plus: Impairment of equity investments
0.00
0.00
0.01
0.00
Plus: Discrete tax items
(0.01
)
(0.00
)
(0.01
)
0.00
Plus: Income tax effect of non-GAAP adjustments 1
(0.01
)
(0.01
)
(0.02
)
(0.02
)
Adjusted earnings (loss) per share – basic
$
0.18
$
0.02
$
0.28
$
(0.09
)
Reconciliation of GAAP to adjusted EPS – diluted
GAAP earnings (loss) per share – diluted
$
0.06
$
(0.09
)
$
0.07
$
(0.27
)
Plus: Share-based compensation expenses
0.10
0.09
0.17
0.16
Plus: Depreciation
0.02
0.02
0.04
0.04
Plus: Amortization of intangibles
0.00
0.00
0.00
0.00
Plus: Other
0.00
0.00
0.00
0.00
Plus: Impairment of equity investments
0.00
0.00
0.01
0.00
Plus: Discrete tax items
(0.01
)
0.00
(0.01
)
0.00
Plus: Income tax effect of non-GAAP adjustments 1
(0.01
)
(0.01
)
(0.02
)
(0.02
)
Adjusted earnings (loss) per share – diluted
$
0.17
$
0.02
$
0.27
$
(0.09
)
Reconciliation of GAAP to adjusted earnings (loss) per ADS – basic
GAAP earnings (loss) per ADS – basic
$
0.87
$
(1.15
)
$
0.89
$
(3.56
)
Plus: Share-based compensation expenses
1.39
1.25
2.29
2.10
Plus: Depreciation
0.28
0.23
0.57
0.46
Plus: Amortization of intangibles
0.05
0.01
0.06
0.02
Plus: Other
0.01
0.00
0.01
0.00
Plus: Impairment of equity investments
0.03
0.00
0.14
0.00
Plus: Discrete tax items
(0.13
)
0.01
(0.08
)
0.02
Plus: Income tax effect of non-GAAP adjustments 1
(0.16
)
(0.13
)
(0.27
)
(0.22
)
Adjusted earnings (loss) per ADS – basic
$
2.33
$
0.22
$
3.61
$
(1.17
)
Reconciliation of GAAP to adjusted earnings (loss) per ADS – diluted
GAAP earnings (loss) per ADS – diluted 2
$
0.84
$
(1.13
)
$
0.85
$
(3.56
)
Plus: Share-based compensation expenses
1.34
1.23
2.20
2.10
Plus: Depreciation
0.27
0.22
0.55
0.46
Plus: Amortization of intangibles
0.05
0.01
0.06
0.02
Plus: Other
0.01
0.00
0.01
0.00
Plus: Impairment of equity investments
0.03
0.00
0.14
0.00
Plus: Discrete tax items
(0.13
)
0.01
(0.08
)
0.02
Plus: Income tax effect of non-GAAP adjustments 1
(0.16
)
(0.13
)
(0.26
)
(0.22
)
Adjusted earnings (loss) per ADS – diluted
$
2.25
$
0.22
$
3.48
$
(1.17
)
Article content
Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.
For the second quarter of 2024, GAAP diluted loss per ADS includes $0.02 loss per ADS attributable to the dilutive ADS outstanding for purposes of this reconciliation. As the Company was in a GAAP net loss position no diluted weighted average shares outstanding were calculated for US GAAP purposes.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Contact
Article content
Article content
Liza Heapes
Article content
Article content
+1 857-302-5663
Article content
Article content
ir@beonemed.com
Article content
Media Contact
Article content
Article content
Kyle Blankenship
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 minutes ago
- Globe and Mail
Moomoo's Parent Company Futu Releases Q2 2025 Results: Net Income up 105% YoY to US$339 Million
JERSEY CITY, N.J. , /CNW/ -- Moomoo's parent company Futu Holdings Ltd. ("Futu" or "the Company") (Nasdaq: FUTU), a leading global tech-driven online brokerage and wealth management platform, announced its unaudited Q2 2025 earnings with US$676.6 million in revenues, up 69.7% year-over-year ("YoY"), and US$338.8 million in non-GAAP adjusted net income, up 105.2% YoY. As of June 30, 2025 , the Company reported 27.12 million registered users, 5.24 million brokerage accounts and 2.88 million funded accounts. The Company's total client assets surged to US$124 billion , demonstrating an accelerated growth of 17% quarter-over-quarter ("QoQ") and 68% YoY. Notably, the Hong Kong market reported strong net inflows, with average client assets increasing QoQ by double digits, while the Singapore market posted robust user growth, with one in every two Singapore residents now a moomoo user [1]. In Q2, the Company's total trading volume across its platforms grew by 12% QoQ and 121% YoY to US$457 billion , with US equities hitting US$343 billion , an all-time high. Singaporean, Australian, Japanese, and Canadian equities also recorded historical highs in quarterly trading volume. Cryptocurrency and AI Lead Product Innovation In the second quarter, cryptocurrency assets grew significantly by 43% QoQ across the Company's platforms. As the Company charts an ambitious course for the future of fintech, it has placed cryptocurrency expansion at the forefront of its business strategy. Following successful launches in Hong Kong and Singapore , the Company has introduced Moomoo Crypto to US investors. It is actively exploring and accelerating the rollout of cryptocurrency trading services across its global markets, aiming to build a one-stop investment platform that seamlessly connects virtual assets with traditional finance. At the same time, the Company is striving to build an end-to-end virtual asset infrastructure lifecycle. Leveraging multiple licenses obtained from regulators of various markets, the Company is set to provide a wide range of services including custody, matching and trading for virtual assets. The Company has launched cryptocurrency deposit and withdrawal services in Hong Kong , and has announced plans to explore offering around-the-clock on-chain tokenized money market fund trading services. In the future, the Company intends to offer more compliant crypto-related features to global investors. In addition to cryptocurrency, Artificial Intelligence ("AI") has been in the spotlight as more AI applications emerge in the fintech realm. In Q2, the Company introduced its self-developed blockbuster feature, Moomoo AI, an AI chatbot that empowers users worldwide to make smarter investment decisions with cutting-edge technologies. More advanced tech-driven functions are available in Moomoo Membership, which aims to provide exclusive premium benefits to members and provide value-added services. The Company continues to upgrade its platform features and enrich its product selections to meet various investor demands. In Japan , moomoo further expanded its capabilities in US stock assets by launching US stock options trading. In Malaysia , moomoo introduced IPO financing and earnings calendar features, enhancing the Malaysian stock trading experience. Meanwhile, the Company is improving trading features across various platforms, including launching the Options Strategy Builder feature on mobile and enabling funds and bonds trading on desktop. The recent Bullish IPO attracted strong interest on moomoo US platform, with 100% of moomoo subscribers successfully securing the shares. The moomoo app maintained the top position in Q2 downloads among local stock trading apps in Australia , Malaysia , Singapore , and Hong Kong [2]. Localization Strategy Drives Long-Term Market Growth In response to the rapid increase in demand for cryptocurrency and options related content from global users, moomoo introduced several dedicated educational sections within the in-app community. By the end of the second quarter, the community reported quarterly growth in daily active users, user generated content, and user engagement, with almost two million visits to the community's free educational online courses. In addition to online courses, moomoo also partnered with various organizations to promote financial literacy. In collaboration with Nasdaq and Japan Exchange Group, moomoo hosted its flagship offline event -- MooFest in Japan , attracting around 3,000 investors. Moomoo Malaysia joined forces with Bursa Malaysia to promote financial literacy, advancing the development of the local investment market. In the US, Moomoo Foundation and W!se, an educational nonprofit, presented awards to 100 high schools for their educational excellence in finance. Additionally, moomoo made a bold new presence at Citi Field, home of the American professional baseball team the New York Mets, with a 36-foot high moomoo signage, which significantly amplifies moomoo's brand visibility and recognition around the New York tri-state area. Moomoo also partnered with J.P. Morgan for the J.P. Morgan Corporate Challenge Singapore 2025 to promote wellness and an active lifestyle. Moomoo's dedicated localization efforts and product strengths garnered wide recognition across global markets, underscoring its growing influence in the fintech domain. In Malaysia , moomoo was honored by Bursa Malaysia with two prestigious awards - "Top Broker - Highest Number of New Accounts" and "Top Broker - Highest Traded Value". In Australia , moomoo secured the "2025 Canstar Outstanding Value" awards for traders, active investors, and casual investors, a testament to its broad appeal and "customer-first" business philosophy. In Singapore , moomoo clinched the "Fintech - Private Wealth Management" award at the SBR Technology Excellence Awards 2025. With all these accolades, moomoo reaffirms its commitment to enhancing customer value. The Company will continue to widen the products and features on the platform while maintaining its first-class services. About moomoo Moomoo is a leading global investment and trading platform dedicated to empowering investors with user-friendly tools, data, and insights. Our platform is designed to provide essential information and technology, enabling users to make well-informed investment decisions. With advanced charting tools, pro-level analytical features, moomoo evolves alongside our users, fostering a dynamic community where investors can share, learn, and grow together. Founded in the US, moomoo has expanded its global presence to serve investors across multiple markets, including Singapore , Australia , Japan , Canada , Malaysia , and New Zealand . As a subsidiary of a Nasdaq-listed company, moomoo is trusted by more than 27 million investors worldwide and has earned recognition from leading financial institutions and publications for its innovation and reliability. SOURCE moomoo
Globe and Mail
13 minutes ago
- Globe and Mail
3 Cheap Stocks Under $100 That Look Like Absolute Steals Right Now
Key Points Pinterest, United Parcel Service, and Comcast are some of the cheapest big-name stocks you can buy right now. They all trade at low earnings multiples and can be strong long-term investments. 10 stocks we like better than Pinterest › If you don't want to chase all-time highs and buy stocks at extremely high valuations, the good news is that there are many decently priced options. And below, I'm going to focus on what I think are some of the best deals available. Three stocks that trade at less than $100 per share and can be bargain buys right now include Pinterest (NYSE: PINS), United Parcel Service (NYSE: UPS), and Comcast (NASDAQ: CMCSA). A couple are facing concerning headwinds, but here's why they can all be great long-term investments. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Pinterest Pinterest is a popular social media site where people go for ideas related to just about anything. Whether it's home renovation projects, baking, or recent shopping hauls, there's a ton of content to sift through. The platform is particularly popular with Gen Z, which Pinterest says accounts for more than 40% of its monthly user base. Entering this week, shares of Pinterest have been trading around $35, and that's with the stock rising 24% since the start of the year. And yet, it's still a cheap buy, trading at just 13 times its trailing earnings. Its price/earnings-to-growth multiple, or PEG, is around 0.8. That's based on analyst expectations over the next five years, and it implies that Pinterest is one heck of a cheap growth stock. The company's top line rose by 17% in its most recent quarter (which ended on June 30), to just under $1 billion. Monthly active users rose by 11% to 578 million. With a market cap of only $24 billion, Pinterest is a business that could get a whole lot more valuable given how popular it is with younger audiences. It can be a terrific long-term buy. United Parcel Service There's not much growth happening for United Parcel Service these days. The logistics company is battling significant macroeconomic headwinds due to tariffs. It's trading at less than $90, and the last time you could have bought the stock at a much cheaper price than that was in 2013. UPS is facing some near-term challenges, but it's hard to not like the business over the long haul. The world of e-commerce is still getting bigger, and demand for global shipments isn't likely to slow down. There may be short-term adversity, but if you're a long-term investor, you don't need to worry too much about UPS given its dominance in the industry. The company is making tough but smart decisions, such as scaling back on volume from Amazon in an effort to improve profitability. And it is profitability, not simply sales, that should drive decisions. Although it may not be a popular move and it may hurt the top line, if it improves profit margins, that could be a big win in the end. UPS is trading at a price-to-earnings multiple (P/E) of 13, and in the long run it could have plenty of upside as economic conditions improve. Comcast Rounding out this list of cheap stocks is media and tech company Comcast. It's trading around $34, and its P/E is less than 6 -- an astoundingly low valuation for one of the largest entertainment companies in the country. Its high debt load (around $100 billion) is undoubtedly turning away a lot of risk-averse investors. But with Comcast spinning off many cable TV networks later this year, that could help reduce costs and allow it to focus on higher-growth opportunities in areas such as streaming. The business may have become too bloated, and simplifying its approach could work well for investors. Overall, Comcast still has excellent brands in its portfolio, and it's highly profitable, with an operating margin of around 20% over the past six months. I'm optimistic that by becoming leaner, the business can be better positioned for growth in the future. At such a cheap valuation, it may be too tempting to pass up since it offers an excellent margin of safety. Should you invest $1,000 in Pinterest right now? Before you buy stock in Pinterest, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pinterest wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
Globe and Mail
13 minutes ago
- Globe and Mail
Zacks.com featured highlights NVIDIA, Vertiv Holdings and Mastercard
For Immediate Release Chicago, IL – August 20, 2025 – The stocks in this week's article are NVIDIA Corp. NVDA, Vertiv Holdings Co. VRT and Mastercard Inc. MA. NVIDIA & 2 Other Profitable Stocks Worth Keeping in 2025 Investors should seek companies that produce strong returns after covering all operating and non-operating expenses. Therefore, it's wise to invest in a profitable company rather than one that is losing money. Here, we use accounting ratios to evaluate a company's profitability. Among various profitability ratios, we choose the most effective and widely used metric to assess a firm's bottom-line performance. To that end, NVIDIA Corp., Vertiv Holdings Co. and Mastercard Inc. have been selected as top picks for the year due to their high net income ratios. Net Income Ratio The net income ratio gives us the exact profitability level of a company. It reflects the percentage of net income to total sales revenues. Using the net income ratio, one can determine a firm's effectiveness in meeting operating and non-operating expenses from revenues. A higher net income ratio usually implies a company's ability to generate ample revenues and successfully manage all business functions. Here are three of the 72 stocks that qualified for the screening: NVIDIA NVIDIA offers solutions for graphics, computing, and networking in the United States, Singapore, Taiwan, China, Hong Kong, and around the world. The 12-month net profit margin of NVDA is 51.7%. NVIDIA has a Zacks Rank #3 (Hold) (read more: Is SMCI Stock the Next NVIDIA, and Is It Worth Buying?). Vertiv Vertiv provides infrastructure technologies and services for global data centers. The 12-month net profit margin of VRT is 8.9%. Vertiv has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here. Mastercard Mastercard offers payment processing services globally, including in the United States. The 12-month net profit margin of MA is 44.9%. Mastercard has a Zacks Rank #2. You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors, and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks' portfolios and strategies are available at: Free: Instant Access to Zacks' Market-Crushing Strategies Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached. Get all the details here >> For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA): Free Stock Analysis Report Vertiv Holdings Co. (VRT): Free Stock Analysis Report
